TNFRSF17 and AL amyloidosis: A number of BCMA targeted therapies have been introduced for relapse refractory multiple myeloma including—(1) CART therapy (Idecabtagene vicleucel and Ciltacabtagene autoleucel), (2) antibody drug conjugate (Belantamab mafodotin), and (3) bispecific antibodies (Teclistamab) [9].